🏷

Classifications

Harrison's Chapter

🔗

Mappings

MONDO

MONDO:0006608 seborrheic dermatitis

Primary MONDO disease identifier for this seborrheic dermatitis entry.

📘

Definitions

2

Clinical syndrome definition for seborrheic dermatitis

Seborrheic dermatitis is a chronic inflammatory eruption of sebaceous-rich skin characterized by erythematous patches or plaques with greasy scale.

CASE_DEFINITION General clinical framing of seborrheic dermatitis in adults and children

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."

This abstract provides a concise syndrome-level clinical definition of seborrheic dermatitis.

Practical diagnostic definition for routine care

Seborrheic dermatitis is usually diagnosed clinically on the basis of a compatible distribution and morphology, with laboratory or instrumental investigations rarely needed unless mimics are suspected.

DIAGNOSTIC_CRITERIA Day-to-day diagnosis of suspected seborrheic dermatitis

Show evidence (1 reference)

PMID:35967915 SUPPORT Human Clinical

"The diagnosis of SD is usually clinical, and specific laboratory and/or instrumental investigations are seldom required."

This supports a practical clinical diagnosis without routine ancillary testing.

◆

Subtypes

2

Adult seborrheic dermatitis

Adult disease predominantly involves the scalp, face, and trunk and follows a chronic relapsing course.

Show evidence (1 reference)

PMID:35967915 SUPPORT Human Clinical

"Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that mostly affects young adults in areas rich in sebaceous glands (scalp, face, and trunk)."

This supports a clinically distinct adult-predominant form centered on sebaceous-rich sites.

Infantile seborrheic dermatitis

Infantile disease typically presents as cradle cap with greasy yellow scale on the scalp and is usually benign and self-limited.

Show evidence (1 reference)

PMID:35967915 SUPPORT Human Clinical

"In infants, it mainly occurs on the scalp as yellowish, scaly patches ("cradle cap")."

This supports infantile seborrheic dermatitis as a recognizable scalp-predominant subtype.

⚙

Pathophysiology

12

Sebaceous gland activity and sebum-rich cutaneous milieu

Seborrheic dermatitis preferentially develops in areas rich in sebaceous glands, and altered sebaceous secretion is treated as one of the proximal disease-promoting factors.

sebocyte link

Show evidence (1 reference)

PMID:35967915 SUPPORT Human Clinical

"Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that mostly affects young adults in areas rich in sebaceous glands (scalp, face, and trunk)."

This supports sebaceous-rich localization as a core organizing feature of seborrheic dermatitis biology.

Malassezia colonization of sebum-rich skin

Colonization of affected skin by Malassezia spp. is a proximal microbial event repeatedly implicated in seborrheic dermatitis pathogenesis.

Show evidence (1 reference)

PMID:20592880 SUPPORT Human Clinical

"Although its pathogenesis is not completely understood, some postulate that the condition results from colonization of the skin of affected individuals with species of the genus Malassezia (formerly, Pityrosporum)."

This overview directly links seborrheic dermatitis pathogenesis to Malassezia colonization.

Malassezia-associated free fatty acid release

Malassezia lipolytic activity can liberate free fatty acids from lipid substrates, creating a plausible irritant intermediary in seborrheic dermatitis.

lipid metabolism link

Show evidence (1 reference)

PMID:27072777 SUPPORT In Vitro

"Conclusion: The effect of lithium succinate on growth of M. yeasts and presumably in SD can be explained by a precipitation of free fatty acids as alkali soaps limiting their availability for the growth of these lipid-dependent yeasts."

This abstract supports free fatty acids as a mechanistically relevant Malassezia-associated intermediate in seborrheic dermatitis.

Keratinocyte TLR2 sensing of Malassezia

Malassezia exposure induces a keratinocyte TLR2/MyD88 innate sensing step.

keratinocyte link

inflammatory response link

Show evidence (1 reference)

PMID:16283346 SUPPORT In Vitro

"When keratinocytes were infected with M. furfur, an up-regulation for TLR2, MyD88, HBD-2, HBD-3 and IL-8 mRNA was demonstrated, compared to the untreated cells."

This supports a distinct keratinocyte innate-sensing step in response to Malassezia.

Keratinocyte chemokine and antimicrobial peptide induction

Malassezia-exposed keratinocytes upregulate IL-8 and beta-defensin transcripts, creating a distinct inflammatory output step.

keratinocyte link

inflammatory response link

Show evidence (1 reference)

PMID:16283346 SUPPORT In Vitro

"The M. furfur-induced increase in HBD-2 and IL-8 gene expression is inhibited by anti-TLR2 neutralising antibodies, suggesting that TLR2 is involved in the M. furfur-induced expression of these molecules."

This supports a distinct mediator-induction step downstream of keratinocyte TLR2 sensing.

NLRP3 inflammasome activation

Malassezia can activate the NLRP3 inflammasome in antigen-presenting cells, promoting IL-1beta-centered innate inflammation.

inflammatory response link NLRP3 inflammasome complex assembly link ⚠ ABNORMAL

Show evidence (1 reference)

PMID:25267545 SUPPORT In Vitro

"Our results identify Malassezia spp. as potential strong inducers of pro-inflammatory responses when taken up by antigen-presenting cells and identify C-type lectin receptors and the NLRP3 inflammasome as crucial actors in this process."

This supports NLRP3 inflammasome activation as a separate mechanistic node rather than a bundled catch-all process.

Cutaneous microbiome dysbiosis

Lesional skin shows a dysbiotic microbiome state involving Malassezia overgrowth together with altered bacterial composition.

Show evidence (1 reference)

PMID:40965103 SUPPORT Human Clinical

"current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."

This supports dysbiosis as a distinct mechanistic node rather than a bundled catch-all process.

Repressed lipid-metabolic programs in lesional skin

Lesional seborrheic dermatitis skin exhibits repression of lipid-metabolic gene programs in parallel with inflammatory activation.

keratinocyte link

lipid metabolism link

Show evidence (1 reference)

PMID:22670617 SUPPORT Human Clinical

"The most striking feature of lesional skin relative to normal was the reciprocal expression of induced inflammatory genes and repressed lipid metabolism genes."

This transcriptomic study identifies lipid-metabolic repression as a distinct lesional abnormality in dandruff/seborrheic dermatitis.

Skin barrier dysfunction

Impaired epidermal barrier integrity is a core pathogenic pillar in seborrheic dermatitis.

keratinocyte link

Show evidence (1 reference)

PMID:40965103 SUPPORT Human Clinical

"current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."

This supports skin barrier dysfunction as one of the principal mechanistic axes in seborrheic dermatitis.

Dysregulated cutaneous inflammation

Lesional seborrheic dermatitis skin shows a persistent inflammatory program rather than a purely microbial colonization state.

keratinocyte link

inflammatory response link

Show evidence (1 reference)

PMID:22670617 SUPPORT Human Clinical

"The most striking feature of lesional skin relative to normal was the reciprocal expression of induced inflammatory genes and repressed lipid metabolism genes."

This study supports an active inflammatory lesional state as a distinct mechanistic feature.

Th1-skewed immune response

Lesional scalp proteomics show T-cell activation with a predominant Th1 immune skew.

T-helper 1 cell link

T-helper 1 type immune response link

Show evidence (1 reference)

PMID:41089687 SUPPORT Human Clinical

"SSD lesional scalps demonstrated significantly greater expressions of proteins related to T-cell/lymphocyte activation, the cytokine storm signaling pathway and the CGAS-STING signaling pathway. Ingenuity pathway analysis (IPA) highlighted Th1 skewing."

This provides direct human lesional evidence for a Th1-biased immune node in seborrheic dermatitis.

Th17/Th22 inflammatory amplification

Additional helper-T-cell inflammatory axes broaden the lesional immune program beyond the dominant Th1 signal.

T-helper 17 cell link

T-helper 17 type immune response link

Show evidence (1 reference)

PMID:41153741 SUPPORT Human Clinical

"Advances in transcriptomic and microbiome profiling have revealed a complex immunoinflammatory environment in SD, involving predominantly Th1, Th17, and Th22 axes."

This identifies Th17 and Th22 pathways as additional inflammatory axes in seborrheic dermatitis.

✶

Histopathology

1

Sebaceous gland atrophy

Scalp biopsies may show smaller, narrowed sebaceous gland lobules, a finding that overlaps with psoriasis and is therefore not disease-specific.

Show evidence (1 reference)

PMID:36222212 SUPPORT Human Clinical

"SGs lobules were smaller and narrower in five of the six cases of seborrheic dermatitis, and SG atrophy was present in four out of six cases."

This pilot study provides direct histopathologic evidence for sebaceous gland atrophy in scalp seborrheic dermatitis.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Greasy scale Dermatological HP:0040189

White-to-yellow greasy scale is especially prominent on the scalp and face.

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."

This abstract directly supports greasy scaling as a defining phenotype of seborrheic dermatitis.

Erythematous patches and plaques Dermatological HP:0025474

Lesions are often ill-defined and occur in sebaceous-rich areas.

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."

This supports erythematous lesions as a core clinical manifestation of seborrheic dermatitis.

Pruritus Dermatological HP:0000989

Itch often contributes substantially to burden of disease, especially with facial involvement.

Show evidence (1 reference)

PMID:20592880 SUPPORT Human Clinical

"It may be associated with pruritus, and it primarily affects sebum-rich areas, such as the scalp, face, upper chest, and back."

This overview explicitly identifies pruritus as a common symptom of seborrheic dermatitis.

Postinflammatory pigment alteration Dermatological HP:0001000

Pigment alteration may accompany seborrheic dermatitis in more richly pigmented skin.

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis."

This review supports pigment alteration as an additional phenotype in seborrheic dermatitis, especially in richly pigmented skin.

💊

Treatments

3

Topical antifungal therapy

Action: pharmacotherapy MAXO:0000058

Topical antifungals are first-line therapy for mild-to-moderate scalp and facial disease to reduce Malassezia burden and inflammation.

Show evidence (1 reference)

PMID:35967915 SUPPORT Human Clinical

"In adults, mild-to-moderate scalp SD forms can be managed with topical antifungals (ketoconazole, ciclopirox, miconazole) or antiinflammatory (mild-to-moderate potency corticosteroids) or keratolytic/humectant (propylene glycol) agents."

This supports topical antifungals as standard therapy for mild-to-moderate scalp seborrheic dermatitis.

Topical corticosteroid or calcineurin inhibitor therapy

Action: pharmacotherapy MAXO:0000058

Topical corticosteroids and calcineurin inhibitors are used to suppress active inflammation, especially in facial or body-fold disease.

Show evidence (1 reference)

PMID:40965088 SUPPORT Human Clinical

"Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis."

This supports topical anti-inflammatory therapy as a mainstay of seborrheic dermatitis management.

Topical roflumilast foam

Action: pharmacotherapy MAXO:0000058

Topical PDE4 inhibition offers a newer noncorticosteroid treatment option for seborrheic dermatitis.

Show evidence (1 reference)

PMID:40965088 SUPPORT Human Clinical

"The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management."

This supports roflumilast foam as an emerging nonsteroidal treatment for seborrheic dermatitis.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Seborrheic Dermatitis:

Atopic dermatitis MONDO:0004980

Overlapping Features Atopic dermatitis can overlap with seborrheic dermatitis when patients present with chronic erythematous scaly facial or scalp eczema.

Distinguishing Features

Atopic dermatitis more often shows diffuse xerosis, flexural eczema, and a broader atopic history.
Seborrheic dermatitis is more tightly centered on sebaceous-rich areas with greasy scale.

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis."

This review explicitly identifies atopic dermatitis as part of the core seborrheic dermatitis differential diagnosis.

Psoriasis MONDO:0005083

Overlapping Features Psoriasis, especially scalp psoriasis or sebopsoriasis-pattern disease, can mimic seborrheic dermatitis with erythema and scale.

Distinguishing Features

Psoriasis more often produces sharply demarcated plaques with thicker silvery scale and may involve nails or extensor sites.
Seborrheic dermatitis more often has ill-defined erythematous patches with greasy yellow-white scale on sebaceous skin.

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis."

This review explicitly identifies psoriasis as a major clinical mimic of seborrheic dermatitis.

Rosacea MONDO:0006604

Overlapping Features Facial seborrheic dermatitis may be confused with rosacea because both can present with persistent centrofacial erythema and inflammatory symptoms.

Distinguishing Features

Rosacea more often features flushing, telangiectasia, and papulopustular facial lesions without prominent greasy scale.
Seborrheic dermatitis more often involves scale-rich erythematous patches in the eyebrows, nasolabial folds, and scalp.

Show evidence (1 reference)

PMID:40965095 SUPPORT Human Clinical

"Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis."

This review explicitly includes rosacea among the principal differential diagnoses for seborrheic dermatitis.

🔬

Clinical Trials

4

NCT04091646 PHASE_II COMPLETED

Phase II double-blind vehicle-controlled trial evaluating topical roflumilast foam 0.3% for seborrheic dermatitis.

Show evidence (1 reference)

clinicaltrials:NCT04091646 SUPPORT Human Clinical

"This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis."

This registry summary supports phase II efficacy and safety evaluation of roflumilast foam in seborrheic dermatitis.

NCT04445987 PHASE_II COMPLETED

Open-label long-term extension study of roflumilast foam 0.3% assessing safety over 52 weeks in seborrheic dermatitis.

Show evidence (1 reference)

clinicaltrials:NCT04445987 SUPPORT Human Clinical

"This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA)."

This registry entry supports long-term safety follow-up of roflumilast foam after the earlier controlled trial.

NCT04973228 PHASE_III COMPLETED

Phase III STRATUM trial evaluating once-daily roflumilast foam 0.3% against vehicle for seborrheic dermatitis.

Show evidence (1 reference)

clinicaltrials:NCT04973228 SUPPORT Human Clinical

"This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis."

This phase III registry summary captures the pivotal trial that underpins later roflumilast use in seborrheic dermatitis.

NCT07404033 PHASE_I NOT_RECRUITING

Early-phase randomized placebo-controlled trial of ZYG24002 lotion in adults with mild-to-moderate seborrheic dermatitis.

Show evidence (1 reference)

clinicaltrials:NCT07404033 SUPPORT Human Clinical

"This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ib clinical trial conducted in adult patients with mild to moderate seborrheic dermatitis (IGA-SD score of 2-3 points)."

This registry summary supports active early-stage therapeutic development beyond roflumilast for seborrheic dermatitis.

📚

Literature Summaries

1

Asta ▸

Asta Literature Retrieval: Seborrheic dermatitis pathophysiology mechanisms phenotypes diagnosis treatment

Asta Scientific Corpus Retrieval 20 citations 2026-03-26T21:53:09.629825

Asta Literature Retrieval: Seborrheic dermatitis pathophysiology mechanisms phenotypes diagnosis treatment

This report is retrieval-only and is generated directly from Asta results.

Papers retrieved: 20
Snippets retrieved: 20

Relevant Papers

[1] Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review

Authors: F. N. Navarro Triviño, Juan Pablo Velasco Amador, Irene Rivera Ruiz
Year: 2025
Venue: Biomedicines
URL: https://www.semanticscholar.org/paper/d12ed36ae782d682e06898ab08286c4a2a3e9842
DOI: 10.3390/biomedicines13102458
PMID: 41153741
PMCID: 12562114
Citations: 5
Influential citations: 0
Summary: An updated overview of the pathophysiological mechanisms of seborrheic dermatitis is provided and new therapeutic approaches are under investigation, including PDE4 inhibitors, topical and oral JAK inhibitors, probiotics, and microbiome-targeted therapies.
Evidence snippets:
Snippet 1 (score: 0.734) > Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review
Snippet 2 (score: 0.597) > The understanding of the mechanisms involved in SD continues to evolve. The current understanding of seborrheic dermatitis recognizes three major pillars in its pathophysiology: alteration of the skin microbiome, dysfunction of sebaceous gland secretion, and the host immune response (Figure 1). A potential fourth factor is genetic predisposition, although its clinical relevance has not yet been fully established.

[2] A narrative review on cutaneous manifestations in polycystic ovary syndrome: pathophysiology, diagnosis, management, and psychosocial impact

Authors: Muhammad Farhan, Ariana Seyfi, Afra Alnuaimi, Maya Alamour, Sarah Alwarafi, Haya Elastal, Muhammad Hashir Nazir, Balakrishnan Kamaraj, Hrithik Dakssesh Putta Nagarajan, Deborah Delianne, S. Ganesan, Tirath Patel
Year: 2025
Venue: Annals of Medicine and Surgery
URL: https://www.semanticscholar.org/paper/08773357a797009e40085ec19ec34c8034ed4433
DOI: 10.1097/MS9.0000000000003217
PMID: 40337376
PMCID: 12055046
Citations: 3
Influential citations: 0
Summary: Cutaneous manifestations in PCOS are a cosmetic concern and an essential diagnostic and therapeutic focus in PCOS, and addressing these features can enhance patient outcomes by mitigating physical symptoms and improving quality of life.

[3] SEBORRHEIC DERMATITIS, SCOPING REVIEW

Authors: Ana Belén Valero Martillo, Valeria Marilú González Ortiz, Ronald Bolívar Farías Requelme, Johanna Maribel Astudillo Romero, José Eduardo Cango Chamba, Bryam Esteban Coello García
Year: 2025
Venue: EPRA international journal of multidisciplinary research
URL: https://www.semanticscholar.org/paper/cf14dc29cf2092eb80526af065a9cbb7fc88b5f2
DOI: 10.36713/epra20013
Citations: 0
Influential citations: 0
Summary: Sborrheic dermatitis has a significant global prevalence, affecting up to 5% of the population, with a higher incidence in individuals with HIV-AIDS, and its pathogenesis has been identified as involving a combination of factors, including Malassezia spp.
Evidence snippets:
Snippet 1 (score: 0.504) > Introduction: Seborrheic dermatitis (SD) is a common skin disease, where its signs and symptoms may differ according to skin color, associated medical conditions, environmental factors, and vehicle preference. Seborrheic dermatitis is a common skin condition in infants, adolescents and adults, characterized by scaling, erythema and itching, especially on the scalp, face, chest, back, armpits and groin. Objective: to detail the current information related to seborrheic dermatitis, etiology, epidemiology, pathophysiology, histopathology, clinical presentation, evaluation, differential diagnosis, treatment and prognosis. Methodology: a total of 29 articles were analyzed in this review, including review and original articles, as well as clinical cases, of which 23 bibliographies were used because the other articles were not relevant for this study. The sources of information were PubMed, Google Scholar and Cochrane; the terms used to search for information in Spanish, Portuguese and English were: sebopsoriasis, seborrheic dermatitis, seborrheic eczema, dandruff and pityriasis capitis. Results: The most relevant results indicate that seborrheic dermatitis has a significant global prevalence, affecting up to 5% of the population, with a higher incidence in individuals with HIV-AIDS. Its pathogenesis has been identified as involving a combination of factors, including Malassezia spp. colonization of the skin, alteration of the cutaneous microbiota and a deregulated immune response. The most effective treatments are topical, particularly antifungal agents such as ketoconazole and low potency corticosteroids, although treatment should be tailored to the individual characteristics of each patient. Despite being a chronic disease in many cases, early diagnosis and proper management allow control of symptoms and improve the quality of life of patients. Conclusions: Seborrheic dermatitis is a common skin disease, with significant prevalence in various ages and groups, especially in people with HIV-AIDS. Its pathogenesis involves factors such as colonization by Malassezia spp, alterations in the cutaneous microbiota and immune dysregulation. Although it may be self-limiting in some cases, in others

[4] Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology

Authors: I. Turchin, L. Albrecht, Sameh Hanna, Dimitrios Kyritsis, W. J. Loo, Charles W Lynde, V. Prajapati, Kerri Purdy, Linda Rochette, M. Wiseman, Daniel Wong, Geeta Yadav, Jensen Yeung, M. Gooderham
Year: 2025
Venue: Journal of Cutaneous Medicine and Surgery
URL: https://www.semanticscholar.org/paper/dec2d60f25432a8bab477cf6fcdda1586759c38e
DOI: 10.1177/12034754251368840
PMID: 40965103
Citations: 2
Influential citations: 0
Summary: An updated overview of seborrheic dermatitis epidemiology, burden of disease, and pathophysiology is provided, highlighting the integral roles of microbiome, inflammation, and skin barrier dysfunction in its pathogenesis.

[5] Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations

Authors: I. Turchin, L. Albrecht, Sameh Hanna, Dimitrios Kyritsis, W. J. Loo, Charles W Lynde, V. Prajapati, Kerri Purdy, Linda Rochette, M. Wiseman, Daniel Wong, Geeta Yadav, Jensen Yeung, M. Gooderham
Year: 2025
Venue: Journal of Cutaneous Medicine and Surgery
URL: https://www.semanticscholar.org/paper/e6881555d3cd8d798a7b2712f9caa15e450c5581
DOI: 10.1177/12034754251368828
PMID: 40965095
Citations: 2
Influential citations: 0
Summary: Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face. Its presentation varies between children and adults, as well as across different skin tones. Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis. Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis. The pathophysiology of seborrheic dermatitis involves a complex interplay between dermatological, neurological, immunological, and microbiome-related factors. The multifaceted nature of seborrheic dermatitis underscores the need for a comprehensive approach to its diagnosis, considering age, skin colour, cultural practices, and comorbidities. This is the second in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.

[6] Current Understanding of Seborrheic Dermatitis: Treatment Options

Authors: I. Turchin, L. Albrecht, Sameh Hanna, Dimitrios Kyritsis, W. J. Loo, Charles W Lynde, V. Prajapati, Kerri Purdy, Linda Rochette, M. Wiseman, Daniel Wong, Geeta Yadav, Jensen Yeung, M. Gooderham
Year: 2025
Venue: Journal of Cutaneous Medicine and Surgery
URL: https://www.semanticscholar.org/paper/f07f5e09fc9c3184a2684fbd43369ac4b4b2b519
DOI: 10.1177/12034754251368824
PMID: 40965088
Citations: 3
Influential citations: 0
Summary: The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management.

[7] Seborrheic Dermatitis: Unraveling mechanisms, clinical fea-tures, and therapeutic possibilities

Authors: Nayra Lurian Nascimento de Souza, Vanessa Prada dos Anjos, Karla Andrade, Pedro Henrique Moura Teixeira, J. Lima, Maria Julia Kapp Bressan, Thayane Ribeiro Durante, Ana Beatriz Franco Arena
Year: 2025
Venue: International Health Sciences Review
URL: https://www.semanticscholar.org/paper/e9e9753f518e33fb85a3ec6c6e05e15df85b8a89
DOI: 10.70164/ihsr.v1i5.86
Citations: 0
Influential citations: 0
Summary: Treatment includes topical antifungals, corticosteroids, calcineurin inhibitors, keratolytic agents, and specific medicated shampoos, while maintenance regimens are crucial to reduce relapse frequency.

[8] Seborrheic dermatitis - pathogenesis, epidemiology and effective treatment - literature review

Authors: Piotr Sobkiewicz, Maciej Józefiak, Joanna Kania, Krzysztof Kania, Maciej Jędrak, Karolina Niekurzak
Year: 2023
Venue: Journal of Education, Health and Sport
URL: https://www.semanticscholar.org/paper/15ed94b90ddc04d39d07b3a677532b738b4ac738
DOI: 10.12775/jehs.2023.38.01.016
Citations: 0
Influential citations: 0
Summary: The Pathogenesis of Seborrheic dermatitis is not fully understood, the exact molecular process needs to be examined and patients should be informed that ongoing maintenance treatment will be required.
Evidence snippets:
Snippet 1 (score: 0.553) > Seborrheic dermatitis - pathogenesis, epidemiology and effective treatment - literature review
Snippet 2 (score: 0.512) > Introduction: Seborrheic dermatitis (SD) is common inflammatory dermatology disease. It’s affect up to 3-8% of the population. SD is characterized by erythema yellowish plaques and different level of itching and scaling. The last two symptoms are important factors that affect the quality of life of patients. This condition is usually a reaction to growth of Malassezia spp and commonly develop in regions of strong sebaceous glands such as the scalp, facial area, chest, back. Other factors include increased activity of sebaceous glands, immunosuppression, and stress. Aim of the study: A review of current stage of knowledge on the pathophysiology, epidemiology of Seborrheic Dermatitis. Recommended management with newest guidelines of this disease. The impact of the Covid-19 pandemic and the use of masks on the incidence of Seborrheic Dermatitis. Material and methods: This review was based on available data searched in the PubMed and Google Scholar by using key words: Seborrheic dermatitis, pathophysiology, epidemiology, diagnosis, treatment, clinical presentation, scalp, infant. Conclusion: The Pathogenesis of Seborrheic dermatitis is not fully understood, the exact molecular process needs to be examined. SD is chronic disease with episode of remission and relapse of symptoms. Patients should be informed that ongoing maintenance treatment will be required. Treatment include topical antifungal (ketoconazole, Ciclopirox olamine, zinc pyrithione) and topical anti-inflammatory drugs like mild or mid-strength corticosteroids or calcineurin inhibitors (off-label use). In severe or resistance cases systematic therapy could be necessary. In this situation antifungal drugs (terbinafine, itraconazole) or low dose of isotretinoin are available options. Also new synergic treatments were introduce like cannabinoids or vitamin D which could make therapy more efficiency.

[9] Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.

Authors: Y. Cavusoglu, A. Çelik, H. Altay, S. Nalbantgil, Ö. Özden, A. Temizhan, D. Ural, Serkan Ünlü, M. Yılmaz, M. Zoghi
Year: 2022
Venue: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
URL: https://www.semanticscholar.org/paper/1e998ee320fce1b7f2cb77dabab598eb2082d136
DOI: 10.5543/tkda.2022.S1
PMID: 35969235
Citations: 8
Influential citations: 0
Summary: A comprehensive review including epidemiology, pathophysiology, clinical presentation and phenotypes of HF-NEF and to guide clinicians for the diagnosis and therapeutic approaches based on the available data in the literature is provided.

[10] Patient and Healthcare Provider Perspectives on the Pathway to Diagnosis of Seborrheic Dermatitis in the United States

Authors: R. Chovatiya, M. Polaskey, Lakshi M. Aldredge, Candrice R Heath, Moises Acevedo, David H Chu, Diane Hanna, M. Seal, M. Zirwas
Year: 2024
Venue: Advances in Therapy
URL: https://www.semanticscholar.org/paper/333ac895ab55d5a97b0d1c122e8491749b989389
DOI: 10.1007/s12325-024-02986-8
PMID: 39347927
PMCID: 11550289
Citations: 1
Influential citations: 0
Summary: Insight into patient and HCP perspectives about SD diagnosis and management from December 2021 to January 2022 highlights the complexities in the diagnostic and management pathways of SD and underscores the need for a more nuanced understanding and approach in addressing the condition.

[11] A Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment.

Authors: Geeta Yadav, Maxwell Sauder, S. Siddha, R. Zeinab, Maxime Barakat, Marissa Joseph
Year: 2026
Venue: Journal of Cutaneous Medicine and Surgery
URL: https://www.semanticscholar.org/paper/4f560e8456c0819800e91e440fb80a65d19c2b28
DOI: 10.1177/12034754261427395
PMID: 41847987
Citations: 0
Influential citations: 0
Summary: This review provides an up-to-date overview of PIH pathophysiology, diagnosis and differential diagnosis, and management, and offers expert clinical commentary on practical strategies for identifying, preventing, and managing PIH in routine practice.

[12] Experts' view on the management of scalp seborrheic dermatitis in Italy.

Authors: B. Piraccini, G. Micali, E. Fulgione, S. Guida, G. Caldarola
Year: 2026
Venue: Journal of dermatological treatment (Print)
URL: https://www.semanticscholar.org/paper/af9480ad447698c0415caf07cec8536a81a8b559
DOI: 10.1080/09546634.2026.2644012
PMID: 41867134
Citations: 0
Influential citations: 0
Summary: This experts' view provides a structured approach to SSD management in Italy, integrating clinical experience and scientific evidence.

[13] Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting

Authors: L. Eichenfield, Stephen Stripling, Selwyn Fung, A. Cha, Andryann O’Brien, L. Schachner
Year: 2022
Venue: Pediatric Drugs
URL: https://www.semanticscholar.org/paper/aff13e2dcb3dccbf496f436dd93f3bf898215377
DOI: 10.1007/s40272-022-00499-x
PMID: 35698002
PMCID: 9191759
Citations: 82
Influential citations: 5
Summary: Recent advances in scientific research regarding the mechanisms involved in the pathogenesis of atopic dermatitis that have resulted in the discovery of novel therapeutic targets and the development of targeted biologic therapies with the potential to revolutionize AD therapy are highlighted.

[14] [Pulmonary hypertension associated with left heart diseases: pathophysiology, diagnosis, treatment].

Authors: S. Caravita, M. Gori, A. Garascia, C. Baratto, Nino Camassa, S. Carigi, Luisa De Gennaro, Renata De Maria, I. Enea, P. Gentile, F. Giordana, Giuseppe Leonardi, F. Lo Giudice, Francesco Orso, Antonella Romaniello, L. Roncon, M. Tinti, M. Vatrano, M. Vedovati, Marco Marini, C. Picariello
Year: 2024
Venue: Giornale italiano di cardiologia
URL: https://www.semanticscholar.org/paper/d3ea5d861459182a6221eaf8852a876f0aa26287
DOI: 10.1714/4187.41757
PMID: 38270364
Citations: 0
Influential citations: 0
Summary: The differential diagnosis of PH associated with left heart disease vs pulmonary arterial hypertension (PAH) is challenging in patients with cardiovascular comorbidities, risk factors for PAH and/or a preserved left ventricular ejection fraction.

[15] Seborrheic dermatitis and dandruff: An overview of pathogenesis, role of Malassezia spp., and natural treatment approaches.

Authors: Imrose Wasim, Nur Shaid Mondal, Joyjeet Dey, Lunasmrita Saikia, Douglas Law, Saikat Sen, M. Gautam, P. Dutta
Year: 2026
Venue: Journal de Mycologie Médicale
URL: https://www.semanticscholar.org/paper/6005f76fd83a8aec020edf65bc6d584aa7bc673b
DOI: 10.1016/j.mycmed.2026.101604
PMID: 41616707
Citations: 0
Influential citations: 0
Summary: The results indicate that Malassezia spp.

[16] Hemodynamic Definitions, Phenotypes, Pathophysiology, and Evaluation of Pulmonary Hypertension Related to Left Heart Disease

Authors: Elizabeth Ghandakly, Akshat Banga, R. Kaw
Year: 2025
Venue: Journal of Cardiovascular Development and Disease
URL: https://www.semanticscholar.org/paper/294014b4609eac9bf9718f01238ffb8b0a9696c0
DOI: 10.3390/jcdd12070238
PMID: 40710764
PMCID: 12295775
Citations: 1
Influential citations: 0
Summary: Pulmonary hypertension can develop from multiple etiologic mechanisms and disease states and molecular pathways that eventually lead to irreversibility of PH can provide another frontier in the pharmacologic management of PH in LHD.

[17] Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series.

Authors: Naiem Issa, Lidia Pomaville
Year: 2025
Venue: ˜The œJournal of clinical and aesthetic dermatology
URL: https://www.semanticscholar.org/paper/5560d7f0b328c373c3fef614831d497d2e521efd
PMID: 39830824
Citations: 3
Influential citations: 0
Summary: Tapinarof cream 1% QD used for the treatment of four adults with mild-to-severe SD, demonstrated a rapid onset of efficacy and noticeable improvements in disease activity, indicating a possible remittive effect as previously described in plaque psoriasis.

[18] Time and headache: Insights into timing processes in primary headache disorders for diagnosis, underlying pathophysiology and treatment implications

Authors: A. González-Martínez, J. Ray, F. Haghdoost, U. Ashraf, Tuba Cerrahoğlu Şirin, Mia Catherine Dantes, Helin Gosalia, Heewon Hwang, Jee Min Kim, K. S. Lange, Felicia Jennysdotter Olofsgård, E. Caronna, P. Pozo‐Rosich
Year: 2024
Venue: Cephalalgia
URL: https://www.semanticscholar.org/paper/08e60eec04b7ad4d229922f17661e374fd6f1091
DOI: 10.1177/03331024241297652
PMID: 39558611
Citations: 11
Influential citations: 0
Summary: A comprehensive analysis of time patterns in primary headache disorders underscores their role in phenotyping, understanding and treating primary headache disorders, offering promising avenues for advancing and tailoring headache management.

[19] [Comprehensive considerations for the diagnosis, treatment, and management of osteogenesis imperfecta].

Authors: Xiangjun Lyu, Jian Dong
Year: 2025
Venue: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
URL: https://www.semanticscholar.org/paper/f2fb75eb848bd7397680b9ce6caabc30704c3514
DOI: 10.7499/j.issn.1008-8830.2505110
PMID: 41401950
Citations: 0
Influential citations: 0
Summary: The genetic and pathophysiological mechanisms, recent advances in diagnosis and treatment, and key points in the management of OI are discussed, aiming to provide up-to-date reference information for OI care and clear, actionable guidance for clinicians.

[20] Diabetic Bone Disease: A Comprehensive Narrative Review of Pathophysiology, Diagnosis, and Evidence-Based Management

Authors: João Protásio Netto, Vagner Camargo Pires, Mariana Garcia Martins Castro
Year: 2025
Venue: Diabetology
URL: https://www.semanticscholar.org/paper/e08b072b28f129b49d8f6663cb7960c38d3457bd
DOI: 10.3390/diabetology6110140
Citations: 0
Influential citations: 0
Summary: Diabetic bone disease represents a distinct clinical entity requiring enhanced diagnostic strategies beyond traditional densitometry, evidence-based treatment selection considering skeletal and metabolic effects, and specialized management protocols extending beyond conventional osteoporosis care.

{ }

Source YAML

click to show

name: Seborrheic Dermatitis
creation_date: '2026-03-26T21:48:42Z'
updated_date: '2026-03-27T15:35:00Z'
category: Complex
description: >-
  Seborrheic dermatitis is a chronic relapsing inflammatory dermatosis of
  sebaceous-rich skin, especially the scalp, face, upper trunk, and body folds.
  Disease expression reflects a multifactorial interaction among Malassezia-
  associated microbiome imbalance, dysregulated cutaneous inflammation, skin
  barrier dysfunction, and sebaceous/lipid abnormalities. Adult disease is
  typically chronic and recurrent, whereas infantile disease often presents as
  cradle cap and is usually self-limited.
definitions:
- name: Clinical syndrome definition for seborrheic dermatitis
  definition_type: CASE_DEFINITION
  description: >-
    Seborrheic dermatitis is a chronic inflammatory eruption of sebaceous-rich
    skin characterized by erythematous patches or plaques with greasy scale.
  scope: General clinical framing of seborrheic dermatitis in adults and children
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."
    explanation: This abstract provides a concise syndrome-level clinical definition of seborrheic dermatitis.
- name: Practical diagnostic definition for routine care
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Seborrheic dermatitis is usually diagnosed clinically on the basis of a
    compatible distribution and morphology, with laboratory or instrumental
    investigations rarely needed unless mimics are suspected.
  scope: Day-to-day diagnosis of suspected seborrheic dermatitis
  evidence:
  - reference: PMID:35967915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SD is usually clinical, and specific laboratory and/or instrumental investigations are seldom required."
    explanation: This supports a practical clinical diagnosis without routine ancillary testing.
synonyms:
- seborrhoeic dermatitis
- seborrheic eczema
disease_term:
  preferred_term: seborrheic dermatitis
  term:
    id: MONDO:0006608
    label: seborrheic dermatitis
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0006608
      label: seborrheic dermatitis
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for this seborrheic dermatitis entry.
classifications:
  harrisons_chapter:
  - classification_value: skin disorder
    evidence:
    - reference: PMID:20592880
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seborrheic dermatitis is a common chronic inflammatory skin condition, characterized by scaling and poorly defined erythematous patches."
      explanation: This supports classification of seborrheic dermatitis as a skin disorder.
parents:
- Dermatological Disease
- Inflammatory Disease
has_subtypes:
- name: Adult
  display_name: Adult seborrheic dermatitis
  description: >-
    Adult disease predominantly involves the scalp, face, and trunk and follows
    a chronic relapsing course.
  evidence:
  - reference: PMID:35967915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that mostly affects young adults in areas rich in sebaceous glands (scalp, face, and trunk)."
    explanation: This supports a clinically distinct adult-predominant form centered on sebaceous-rich sites.
- name: Infantile
  display_name: Infantile seborrheic dermatitis
  description: >-
    Infantile disease typically presents as cradle cap with greasy yellow scale
    on the scalp and is usually benign and self-limited.
  evidence:
  - reference: PMID:35967915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In infants, it mainly occurs on the scalp as yellowish, scaly patches (\"cradle cap\")."
    explanation: This supports infantile seborrheic dermatitis as a recognizable scalp-predominant subtype.
infectious_agent:
- name: Malassezia
  infectious_agent_term:
    preferred_term: Malassezia
    term:
      id: NCBITaxon:55193
      label: Malassezia
  description: >-
    Malassezia is a lipophilic yeast genus associated with seborrheic
    dermatitis as a colonization- and dysbiosis-related contributor rather than
    a uniformly sufficient infectious cause. Overgrowth on sebaceous skin is
    thought to amplify inflammation in susceptible hosts.
  evidence:
  - reference: PMID:40965103
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."
    explanation: This review supports Malassezia overgrowth as part of the dysbiotic microbial component of seborrheic dermatitis rather than as a stand-alone infectious mechanism.
  - reference: PMID:35967915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In adults, several environmental triggers are likely to promote SD development, along with fungal colonization by Malassezia spp., sebaceous gland activity, as well as immunosuppression, endocrine, neurogenic and iatrogenic factors."
    explanation: This review places Malassezia colonization among multiple interacting contributors to adult seborrheic dermatitis.
prevalence:
- population: General population
  notes: Reported prevalence range is 3-5%.
  evidence:
  - reference: PMID:19111149
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the general population, the prevalence of seborrheic dermatitis varies between 3% and 5%, while in HIV positive patients there is an increased prevalence of seborrheic dermatitis ranging between 30% and 83%."
    explanation: This review gives the commonly cited prevalence range for seborrheic dermatitis in the general population.
- population: People living with HIV
  notes: Reported prevalence range is 30-83%.
  evidence:
  - reference: PMID:19111149
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the general population, the prevalence of seborrheic dermatitis varies between 3% and 5%, while in HIV positive patients there is an increased prevalence of seborrheic dermatitis ranging between 30% and 83%."
    explanation: This review documents marked enrichment of seborrheic dermatitis among people living with HIV.
progression:
- phase: Adult disease course
  duration: Chronic relapsing
  notes: Adult seborrheic dermatitis typically requires recurrent symptom control and maintenance care.
  evidence:
  - reference: PMID:37325288
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Scalp seborrheic dermatitis (SSD) is a prevalent chronic, relapsing inflammatory skin disease."
    explanation: This supports a chronic relapsing disease course for scalp-predominant adult seborrheic dermatitis.
- phase: Infantile disease course
  duration: Weeks to months, rarely years
  notes: Infantile disease is usually self-limited even when treatment evidence remains sparse.
  evidence:
  - reference: PMID:30828791
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infantile seborrhoeic dermatitis (ISD) is a chronic, inflammatory, scaling skin condition, which causes redness and a greasy scaling rash in infants and young children. It can last from weeks to months, but rarely years."
    explanation: This supports the typical time course of infantile seborrheic dermatitis.
pathophysiology:
- name: Sebaceous gland activity and sebum-rich cutaneous milieu
  description: >-
    Seborrheic dermatitis preferentially develops in areas rich in sebaceous
    glands, and altered sebaceous secretion is treated as one of the proximal
    disease-promoting factors.
  cell_types:
  - preferred_term: sebocyte
    term:
      id: CL:0000317
      label: sebocyte
  downstream:
  - target: Malassezia colonization of sebum-rich skin
    description: A lipid-rich sebaceous surface provides a permissive environment for lipophilic Malassezia persistence.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lipid-rich skin surface environment
    evidence:
    - reference: PMID:35967915
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In adults, several environmental triggers are likely to promote SD development, along with fungal colonization by Malassezia spp., sebaceous gland activity, as well as immunosuppression, endocrine, neurogenic and iatrogenic factors."
      explanation: This places sebaceous gland activity alongside Malassezia colonization as a proximal driver of adult seborrheic dermatitis.
    - reference: PMID:41153741
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Its etiology is multifactorial, involving sebaceous gland activity, immune dysregulation, skin barrier dysfunction, and alterations in the microbiome, particularly an overgrowth of Malassezia spp."
      explanation: This review supports a mechanistic relationship between sebaceous activity and Malassezia-predominant microbial disturbance.
  evidence:
  - reference: PMID:35967915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that mostly affects young adults in areas rich in sebaceous glands (scalp, face, and trunk)."
    explanation: This supports sebaceous-rich localization as a core organizing feature of seborrheic dermatitis biology.
- name: Malassezia colonization of sebum-rich skin
  description: >-
    Colonization of affected skin by Malassezia spp. is a proximal microbial
    event repeatedly implicated in seborrheic dermatitis pathogenesis.
  downstream:
  - target: Malassezia-associated free fatty acid release
    description: Malassezia lipid hydrolysis can release free fatty acids from lipid substrates, adding an irritant intermediary step.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27072777
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "An assay based on the hydrolysis of ethyl octanoate enables us to test the hydrolytic activity of reference strains of the species M. globosa, M. sympodialis and M. furfur solely without interference by fungal growth as the free octanoic acid generated has antifungal activity."
      explanation: This demonstrates Malassezia lipolytic activity with free fatty acid generation, supporting an intermediate lipid-hydrolysis step relevant to seborrheic dermatitis.
  - target: Keratinocyte TLR2 sensing of Malassezia
    description: Malassezia exposure elicits keratinocyte innate receptor signaling.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16283346
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "When keratinocytes were infected with M. furfur, an up-regulation for TLR2, MyD88, HBD-2, HBD-3 and IL-8 mRNA was demonstrated, compared to the untreated cells."
      explanation: This supports a direct transition from Malassezia exposure to keratinocyte TLR2/MyD88 innate sensing.
  - target: NLRP3 inflammasome activation
    description: Malassezia exposure can activate an inflammasome branch in innate immune cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25267545
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Here, we show that different Malassezia species could induce NLRP3 inflammasome activation and subsequent IL-1β secretion in human antigen-presenting cells."
      explanation: This supports Malassezia-triggered inflammasome activation as a distinct innate immune branch.
  - target: Cutaneous microbiome dysbiosis
    description: Malassezia overgrowth contributes directly to the dysbiotic microbiome state observed in seborrheic dermatitis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40965103
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."
      explanation: This explicitly places Malassezia overgrowth within the microbiome dysbiosis axis of seborrheic dermatitis.
  evidence:
  - reference: PMID:20592880
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although its pathogenesis is not completely understood, some postulate that the condition results from colonization of the skin of affected individuals with species of the genus Malassezia (formerly, Pityrosporum)."
    explanation: This overview directly links seborrheic dermatitis pathogenesis to Malassezia colonization.
- name: Malassezia-associated free fatty acid release
  description: >-
    Malassezia lipolytic activity can liberate free fatty acids from lipid
    substrates, creating a plausible irritant intermediary in seborrheic
    dermatitis.
  biological_processes:
  - preferred_term: lipid metabolism
    term:
      id: GO:0006629
      label: lipid metabolic process
  evidence:
  - reference: PMID:27072777
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Conclusion: The effect of lithium succinate on growth of M. yeasts and presumably in SD can be explained by a precipitation of free fatty acids as alkali soaps limiting their availability for the growth of these lipid-dependent yeasts."
    explanation: This abstract supports free fatty acids as a mechanistically relevant Malassezia-associated intermediate in seborrheic dermatitis.
- name: Keratinocyte TLR2 sensing of Malassezia
  description: >-
    Malassezia exposure induces a keratinocyte TLR2/MyD88 innate sensing step.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  downstream:
  - target: Keratinocyte chemokine and antimicrobial peptide induction
    description: TLR2-linked sensing promotes inflammatory mediator and beta-defensin transcription in keratinocytes.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16283346
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The M. furfur-induced increase in HBD-2 and IL-8 gene expression is inhibited by anti-TLR2 neutralising antibodies, suggesting that TLR2 is involved in the M. furfur-induced expression of these molecules."
      explanation: This directly links keratinocyte TLR2 sensing to downstream inflammatory mediator induction.
  evidence:
  - reference: PMID:16283346
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "When keratinocytes were infected with M. furfur, an up-regulation for TLR2, MyD88, HBD-2, HBD-3 and IL-8 mRNA was demonstrated, compared to the untreated cells."
    explanation: This supports a distinct keratinocyte innate-sensing step in response to Malassezia.
- name: Keratinocyte chemokine and antimicrobial peptide induction
  description: >-
    Malassezia-exposed keratinocytes upregulate IL-8 and beta-defensin
    transcripts, creating a distinct inflammatory output step.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  downstream:
  - target: Dysregulated cutaneous inflammation
    description: Keratinocyte inflammatory mediator production contributes to the broader lesional inflammatory program.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16283346
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "When keratinocytes were infected with M. furfur, an up-regulation for TLR2, MyD88, HBD-2, HBD-3 and IL-8 mRNA was demonstrated, compared to the untreated cells."
      explanation: This supports keratinocyte mediator induction as a proximal contributor to cutaneous inflammation.
  evidence:
  - reference: PMID:16283346
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The M. furfur-induced increase in HBD-2 and IL-8 gene expression is inhibited by anti-TLR2 neutralising antibodies, suggesting that TLR2 is involved in the M. furfur-induced expression of these molecules."
    explanation: This supports a distinct mediator-induction step downstream of keratinocyte TLR2 sensing.
- name: NLRP3 inflammasome activation
  description: >-
    Malassezia can activate the NLRP3 inflammasome in antigen-presenting cells,
    promoting IL-1beta-centered innate inflammation.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: NLRP3 inflammasome complex assembly
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
    modifier: ABNORMAL
  downstream:
  - target: Dysregulated cutaneous inflammation
    description: Inflammasome activation amplifies pro-inflammatory cytokine release in lesional skin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25267545
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Here, we show that different Malassezia species could induce NLRP3 inflammasome activation and subsequent IL-1β secretion in human antigen-presenting cells."
      explanation: This supports inflammasome-driven cytokine maturation as a distinct innate inflammatory branch triggered by Malassezia.
  evidence:
  - reference: PMID:25267545
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our results identify Malassezia spp. as potential strong inducers of pro-inflammatory responses when taken up by antigen-presenting cells and identify C-type lectin receptors and the NLRP3 inflammasome as crucial actors in this process."
    explanation: This supports NLRP3 inflammasome activation as a separate mechanistic node rather than a bundled catch-all process.
- name: Cutaneous microbiome dysbiosis
  description: >-
    Lesional skin shows a dysbiotic microbiome state involving Malassezia
    overgrowth together with altered bacterial composition.
  downstream:
  - target: Dysregulated cutaneous inflammation
    description: Microbiome imbalance is linked to inflammatory activation in affected skin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40965103
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."
      explanation: This review directly couples microbiome dysbiosis with dysregulated inflammatory responses in seborrheic dermatitis.
  evidence:
  - reference: PMID:40965103
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."
    explanation: This supports dysbiosis as a distinct mechanistic node rather than a bundled catch-all process.
- name: Repressed lipid-metabolic programs in lesional skin
  description: >-
    Lesional seborrheic dermatitis skin exhibits repression of lipid-metabolic
    gene programs in parallel with inflammatory activation.
  biological_processes:
  - preferred_term: lipid metabolism
    term:
      id: GO:0006629
      label: lipid metabolic process
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  downstream:
  - target: Skin barrier dysfunction
    description: Altered epidermal lipid handling is consistent with impaired barrier integrity in lesional skin.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered epidermal lipid composition
    evidence:
    - reference: PMID:22670617
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most striking feature of lesional skin relative to normal was the reciprocal expression of induced inflammatory genes and repressed lipid metabolism genes."
      explanation: This supports lipid dysregulation as a plausible upstream contributor to barrier impairment in seborrheic dermatitis lesions.
  evidence:
  - reference: PMID:22670617
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most striking feature of lesional skin relative to normal was the reciprocal expression of induced inflammatory genes and repressed lipid metabolism genes."
    explanation: This transcriptomic study identifies lipid-metabolic repression as a distinct lesional abnormality in dandruff/seborrheic dermatitis.
- name: Skin barrier dysfunction
  description: >-
    Impaired epidermal barrier integrity is a core pathogenic pillar in
    seborrheic dermatitis.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  downstream:
  - target: Greasy scale
    description: Barrier and cornified-layer instability contributes to persistent visible scaling on affected sebaceous skin.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - abnormal desquamation
    evidence:
    - reference: PMID:40965103
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."
      explanation: This identifies barrier dysfunction as a major pathophysiologic factor supporting its placement upstream of the scaling phenotype.
    - reference: PMID:40965095
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."
      explanation: This supports greasy scaling as the clinical outcome requiring a proximal barrier and desquamation mechanism.
  evidence:
  - reference: PMID:40965103
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction."
    explanation: This supports skin barrier dysfunction as one of the principal mechanistic axes in seborrheic dermatitis.
- name: Dysregulated cutaneous inflammation
  description: >-
    Lesional seborrheic dermatitis skin shows a persistent inflammatory program
    rather than a purely microbial colonization state.
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  downstream:
  - target: Erythematous patches and plaques
    description: Inflammatory activation in lesional skin manifests clinically as erythematous patches and plaques.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40965095
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."
      explanation: This supports erythematous lesions as the direct clinical manifestation of cutaneous inflammation.
  - target: Pruritus
    description: Inflammatory mediators in affected skin contribute to the itch phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20592880
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It may be associated with pruritus, and it primarily affects sebum-rich areas, such as the scalp, face, upper chest, and back."
      explanation: This supports pruritus as a downstream symptom of the inflammatory skin process in seborrheic dermatitis.
  evidence:
  - reference: PMID:22670617
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most striking feature of lesional skin relative to normal was the reciprocal expression of induced inflammatory genes and repressed lipid metabolism genes."
    explanation: This study supports an active inflammatory lesional state as a distinct mechanistic feature.
- name: Th1-skewed immune response
  description: >-
    Lesional scalp proteomics show T-cell activation with a predominant Th1
    immune skew.
  biological_processes:
  - preferred_term: T-helper 1 type immune response
    term:
      id: GO:0042088
      label: T-helper 1 type immune response
  cell_types:
  - preferred_term: T-helper 1 cell
    term:
      id: CL:0000545
      label: T-helper 1 cell
  downstream:
  - target: Dysregulated cutaneous inflammation
    description: Th1-associated immune signaling reinforces the inflammatory program in lesional scalp skin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41089687
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "SSD lesional scalps demonstrated significantly greater expressions of proteins related to T-cell/lymphocyte activation, the cytokine storm signaling pathway and the CGAS-STING signaling pathway. Ingenuity pathway analysis (IPA) highlighted Th1 skewing."
      explanation: This proteomic study directly supports Th1-skewed activation as an upstream inflammatory driver in scalp seborrheic dermatitis.
  evidence:
  - reference: PMID:41089687
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SSD lesional scalps demonstrated significantly greater expressions of proteins related to T-cell/lymphocyte activation, the cytokine storm signaling pathway and the CGAS-STING signaling pathway. Ingenuity pathway analysis (IPA) highlighted Th1 skewing."
    explanation: This provides direct human lesional evidence for a Th1-biased immune node in seborrheic dermatitis.
- name: Th17/Th22 inflammatory amplification
  description: >-
    Additional helper-T-cell inflammatory axes broaden the lesional immune
    program beyond the dominant Th1 signal.
  biological_processes:
  - preferred_term: T-helper 17 type immune response
    term:
      id: GO:0072538
      label: T-helper 17 type immune response
  cell_types:
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  downstream:
  - target: Dysregulated cutaneous inflammation
    description: Th17/Th22-associated signaling broadens and sustains the inflammatory environment in lesional skin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41153741
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Advances in transcriptomic and microbiome profiling have revealed a complex immunoinflammatory environment in SD, involving predominantly Th1, Th17, and Th22 axes."
      explanation: This review supports Th17/Th22 contributions as reinforcing components of the seborrheic dermatitis inflammatory program.
  evidence:
  - reference: PMID:41153741
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Advances in transcriptomic and microbiome profiling have revealed a complex immunoinflammatory environment in SD, involving predominantly Th1, Th17, and Th22 axes."
    explanation: This identifies Th17 and Th22 pathways as additional inflammatory axes in seborrheic dermatitis.
phenotypes:
- name: Greasy scale
  category: Dermatological
  diagnostic: true
  notes: White-to-yellow greasy scale is especially prominent on the scalp and face.
  phenotype_term:
    preferred_term: greasy scale
    term:
      id: HP:0040189
      label: Scaling skin
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."
    explanation: This abstract directly supports greasy scaling as a defining phenotype of seborrheic dermatitis.
- name: Erythematous patches and plaques
  category: Dermatological
  diagnostic: true
  notes: Lesions are often ill-defined and occur in sebaceous-rich areas.
  phenotype_term:
    preferred_term: erythematous patches and plaques
    term:
      id: HP:0025474
      label: Erythematous plaque
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face."
    explanation: This supports erythematous lesions as a core clinical manifestation of seborrheic dermatitis.
- name: Pruritus
  category: Dermatological
  notes: Itch often contributes substantially to burden of disease, especially with facial involvement.
  phenotype_term:
    preferred_term: pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: PMID:20592880
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It may be associated with pruritus, and it primarily affects sebum-rich areas, such as the scalp, face, upper chest, and back."
    explanation: This overview explicitly identifies pruritus as a common symptom of seborrheic dermatitis.
- name: Postinflammatory pigment alteration
  category: Dermatological
  notes: Pigment alteration may accompany seborrheic dermatitis in more richly pigmented skin.
  phenotype_term:
    preferred_term: postinflammatory pigment alteration
    term:
      id: HP:0001000
      label: Abnormality of skin pigmentation
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis."
    explanation: This review supports pigment alteration as an additional phenotype in seborrheic dermatitis, especially in richly pigmented skin.
histopathology:
- name: Sebaceous gland atrophy
  description: >-
    Scalp biopsies may show smaller, narrowed sebaceous gland lobules, a
    finding that overlaps with psoriasis and is therefore not disease-specific.
  evidence:
  - reference: PMID:36222212
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SGs lobules were smaller and narrower in five of the six cases of seborrheic dermatitis, and SG atrophy was present in four out of six cases."
    explanation: This pilot study provides direct histopathologic evidence for sebaceous gland atrophy in scalp seborrheic dermatitis.
treatments:
- name: Topical antifungal therapy
  description: >-
    Topical antifungals are first-line therapy for mild-to-moderate scalp and
    facial disease to reduce Malassezia burden and inflammation.
  context: Mild-to-moderate scalp or facial seborrheic dermatitis
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: antifungal agent
        term:
          id: NCIT:C514
          label: Antifungal Agent
  evidence:
  - reference: PMID:35967915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In adults, mild-to-moderate scalp SD forms can be managed with topical antifungals (ketoconazole, ciclopirox, miconazole) or antiinflammatory (mild-to-moderate potency corticosteroids) or keratolytic/humectant (propylene glycol) agents."
    explanation: This supports topical antifungals as standard therapy for mild-to-moderate scalp seborrheic dermatitis.
- name: Topical corticosteroid or calcineurin inhibitor therapy
  description: >-
    Topical corticosteroids and calcineurin inhibitors are used to suppress
    active inflammation, especially in facial or body-fold disease.
  context: Active inflammatory seborrheic dermatitis, especially facial or intertriginous disease
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: therapeutic corticosteroid
        term:
          id: NCIT:C211
          label: Therapeutic Corticosteroid
  evidence:
  - reference: PMID:40965088
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis."
    explanation: This supports topical anti-inflammatory therapy as a mainstay of seborrheic dermatitis management.
- name: Topical roflumilast foam
  description: >-
    Topical PDE4 inhibition offers a newer noncorticosteroid treatment option
    for seborrheic dermatitis.
  context: Noncorticosteroid topical option for recurrent or treatment-persistent seborrheic dermatitis
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
  evidence:
  - reference: PMID:40965088
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management."
    explanation: This supports roflumilast foam as an emerging nonsteroidal treatment for seborrheic dermatitis.
differential_diagnoses:
- name: Atopic dermatitis
  disease_term:
    preferred_term: atopic dermatitis
    term:
      id: MONDO:0004980
      label: atopic eczema
  description: >-
    Atopic dermatitis can overlap with seborrheic dermatitis when patients
    present with chronic erythematous scaly facial or scalp eczema.
  distinguishing_features:
  - Atopic dermatitis more often shows diffuse xerosis, flexural eczema, and a broader atopic history.
  - Seborrheic dermatitis is more tightly centered on sebaceous-rich areas with greasy scale.
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis."
    explanation: This review explicitly identifies atopic dermatitis as part of the core seborrheic dermatitis differential diagnosis.
- name: Psoriasis
  disease_term:
    preferred_term: psoriasis
    term:
      id: MONDO:0005083
      label: psoriasis
  description: >-
    Psoriasis, especially scalp psoriasis or sebopsoriasis-pattern disease, can
    mimic seborrheic dermatitis with erythema and scale.
  distinguishing_features:
  - Psoriasis more often produces sharply demarcated plaques with thicker silvery scale and may involve nails or extensor sites.
  - Seborrheic dermatitis more often has ill-defined erythematous patches with greasy yellow-white scale on sebaceous skin.
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis."
    explanation: This review explicitly identifies psoriasis as a major clinical mimic of seborrheic dermatitis.
- name: Rosacea
  disease_term:
    preferred_term: rosacea
    term:
      id: MONDO:0006604
      label: rosacea
  description: >-
    Facial seborrheic dermatitis may be confused with rosacea because both can
    present with persistent centrofacial erythema and inflammatory symptoms.
  distinguishing_features:
  - Rosacea more often features flushing, telangiectasia, and papulopustular facial lesions without prominent greasy scale.
  - Seborrheic dermatitis more often involves scale-rich erythematous patches in the eyebrows, nasolabial folds, and scalp.
  evidence:
  - reference: PMID:40965095
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis."
    explanation: This review explicitly includes rosacea among the principal differential diagnoses for seborrheic dermatitis.
clinical_trials:
- name: NCT04091646
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase II double-blind vehicle-controlled trial evaluating topical
    roflumilast foam 0.3% for seborrheic dermatitis.
  evidence:
  - reference: clinicaltrials:NCT04091646
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis."
    explanation: This registry summary supports phase II efficacy and safety evaluation of roflumilast foam in seborrheic dermatitis.
- name: NCT04445987
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Open-label long-term extension study of roflumilast foam 0.3% assessing
    safety over 52 weeks in seborrheic dermatitis.
  evidence:
  - reference: clinicaltrials:NCT04445987
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA)."
    explanation: This registry entry supports long-term safety follow-up of roflumilast foam after the earlier controlled trial.
- name: NCT04973228
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase III STRATUM trial evaluating once-daily roflumilast foam 0.3%
    against vehicle for seborrheic dermatitis.
  evidence:
  - reference: clinicaltrials:NCT04973228
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis."
    explanation: This phase III registry summary captures the pivotal trial that underpins later roflumilast use in seborrheic dermatitis.
- name: NCT07404033
  phase: PHASE_I
  status: NOT_RECRUITING
  description: >-
    Early-phase randomized placebo-controlled trial of ZYG24002 lotion in
    adults with mild-to-moderate seborrheic dermatitis.
  evidence:
  - reference: clinicaltrials:NCT07404033
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ib clinical trial conducted in adult patients with mild to moderate seborrheic dermatitis (IGA-SD score of 2-3 points)."
    explanation: This registry summary supports active early-stage therapeutic development beyond roflumilast for seborrheic dermatitis.
  notes: ClinicalTrials.gov lists this study as Phase Ib and not yet recruiting; mapped to schema enums PHASE_I and NOT_RECRUITING.
datasets: []